Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
Status:
Completed
Trial end date:
2018-07-02
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active
comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and
safety of GDC-0853 in participants with moderate to severe active RA and an inadequate
response to previous methotrexate (MTX) therapy (Cohort 1) or MTX and tumor necrosis factor
(TNF) therapy who may have also had exposure to no more than one non-TNF inhibitor biologic
(Cohort 2).
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Adalimumab Folic Acid Methotrexate Vitamin B Complex